Profil bibliographique

Muzamil Nsibuka Kisekka

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

11Publications signalées

157Citations signalées

0Affiliations récentes

Domaines associés

HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV-related health complications and treatmentsPharmaceutical studies and practicesTuberculosis Research and Epidemiology

Publications récentes

2026 articleOpenAlex

Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial

Anne E M Kamphuis, Nicolas Salvadori, Hilda Angela Mujuru, Mutsawashe Bwakura-Dangarembizi et autres

0 citationsThe Lancet HIV

Accès ouvert 2026 articleOpenAlex

Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial

Adeodata Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, Cissy Kityo et autres

0 citationsThe Lancet HIV

Accès ouvert 2026 articleOpenAlex

Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

Anna Turkova, Ellen White, Avy Violari, Hilda A Mujuru et autres

2 citationsThe Lancet Child & Adolescent Health

Accès ouvert 2026 articleOpenAlex

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, Cecilia Kiilu et autres

1 citationContemporary Clinical Trials

Accès ouvert 2025 articleOpenAlex

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial

Lisanne A. H. Bevers, Gabriela Toledo, Muzamil Kisekka, Isabelle Déprez et autres

3 citationsEBioMedicine

Accès ouvert 2024 articleOpenAlex

A clinical research site pharmacy for the division of AIDS sponsored clinical trials in a low middle income country

Rogers Sekabira, Godwin Murungi, Nigel Okot Kirinya, Muzamil Nsibuka Kisekka et autres

0 citationsInternational Journal of Scientific Reports

Accès ouvert 2023 articleOpenAlex

Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

Anna Turkova, Ellen White, Adeodata Kekitiinwa, Vivian Mumbiro et autres

11 citationsThe Lancet Child & Adolescent Health

Accès ouvert 2023 articleOpenAlex

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

Alexandra Compagnucci, Man K. Chan, Yacine Saïdi, Tim R. Cressey et autres

16 citationsEClinicalMedicine

Accès ouvert 2022 articleOpenAlex

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Pauline Amuge, Abbas Lugemwa, Ben Wynne, Hilda Mujuru et autres

33 citationsThe Lancet HIV

Accès ouvert 2022 articleOpenAlex

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Anna Turkova, Hylke Waalewijn, Man K. Chan, Pauline Bollen et autres

24 citationsThe Lancet HIV

Accès ouvert 2020 articleOpenAlex

Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa

Lynda Stranix‐Chibanda, Peter L. Anderson, Deborah Kacanek, Sybil Hosek et autres

67 citationsClinical Infectious Diseases

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.